# Serine/Glycine-Restricted Diet With Chemoradiotherapy for Rectal Cancer

Source: https://onco.cc/trials/nct07811076/  
OnCo record `nct07811076` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in colorectal cancer, run by Xuelei Ma MD, not yet recruiting.

## Summary

Serine/Glycine-Restricted Diet With Chemoradiotherapy for Rectal Cancer is a phase 1/2, randomised interventional study registered as NCT07811076 by Xuelei Ma MD, with a registry enrolment figure of 140 participants, started 2026-08-31 and due to reach its primary completion in 2027-01-31. Interventions recorded: Serine/Glycine-Restricted Diet; CAPOX Chemotherapy; PD-1 Inhibitor; Short-Course Radiotherapy. Conditions listed: Locally Advanced Rectal Cancer (LARC). Primary outcome: Complete Response Rate (pCR + cCR). Colorectal eligibility wording from the registry: "* Histologically confirmed locally advanced rectal cancer staged as cT3, cT4, or node-positive by pelvic MRI". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: SG-RCT
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07811076
- Phase: 1/2
- Setting: A Randomized Controlled Trial of Serine/Glycine-Restricted Diet Combined With Chemoradiotherapy and Immunotherapy for Neoadjuvant Treatment of Rectal Cancer
- Sponsor: Xuelei Ma MD
- Enrolled: 140

## Sources

- ClinicalTrials.gov NCT07811076: https://clinicaltrials.gov/study/NCT07811076

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07811076.json